Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Acquisition Targets Protein Misfolding

by Ann M. Thayer
September 6, 2010 | A version of this story appeared in Volume 88, Issue 36

Pfizer will purchase privately held FoldRx Pharmaceuticals, of Cambridge, Mass., for an undisclosed upfront fee and future milestone payments. FoldRx develops small-molecule drugs to treat chronic diseases resulting from protein misfolding and aggregation. It has filed for European regulatory approval of its lead product candidate, tafamidis meglumine, as a treatment for the genetic neurodegenerative disease transthyretin amyloid polyneuropathy. Pfizer will fold the company into its specialty care business unit, which focuses in part on orphan and rare diseases.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.